A meta-analysis of 13 trials with 35,563 participants found that once-weekly GLP-1 receptor agonists significantly reduced non-fatal stroke and multiple cardiovascular risk factors in type 2 diabetes patients with coronary artery disease.
35,563 participantsAcross 13 randomized trials, once-weekly GLP-1 receptor agonists significantly reduced non-fatal stroke and six cardiovascular risk factors
What the researchers found
Across 13 randomized controlled trials with 35,563 participants:
- Dulaglutide, exenatide, and semaglutide all outperformed placebo for cardiovascular outcomes in T2DM patients with coronary artery disease
- Significant reduction in non-fatal stroke incidence (p<0.00)
- Significant reductions compared to conventional treatment in:
- HbA1c (p<0.00)
- Fasting blood glucose (p<0.00)
- Body weight (p<0.00)
- Systolic blood pressure (p<0.00)
- Total cholesterol (p<0.00)
- LDL cholesterol (p<0.00)
Network pharmacology analysis identified the renin-angiotensin system as a key pathway, with matrix metalloproteinase 2 (MMP2) and renin as potential key targets. Each GLP-1 RA had distinct molecular target profiles (dulaglutide: 4 targets, exenatide: 5, semaglutide: 2).
Why it matters
Coronary artery disease is the leading killer of people with type 2 diabetes. This large meta-analysis provides strong evidence that once-weekly GLP-1 drugs — already prescribed for blood sugar and weight — deliver meaningful cardiovascular protection on top of their metabolic benefits. The identification of the renin-angiotensin system as a mechanistic pathway is particularly interesting because it suggests GLP-1 drugs may complement ACE inhibitors and ARBs that target the same system.
How the study worked
This was a systematic review and meta-analysis searching Chinese and English databases for randomized controlled trials of once-weekly GLP-1 RAs in T2DM patients with coronary artery disease. Pooled analyses evaluated cardiovascular outcomes and risk factor improvements. Network pharmacology analysis was used to identify potential molecular mechanisms, mapping drug targets to biological pathways.
What this study cannot tell us
The meta-analysis combines trials with different designs, populations, and GLP-1 RA formulations, introducing heterogeneity. The network pharmacology analysis is computational and predictive — the identified targets (MMP2, renin) need experimental validation. The study focused only on once-weekly GLP-1 RAs, so results may not apply to daily formulations. Some of the included trials may have had different primary endpoints and follow-up periods.
How to read the evidence
This is a meta-analysis of 13 randomized controlled trials — the highest level of clinical evidence. The large combined sample size provides strong statistical power. The addition of network pharmacology for mechanistic insight is novel but computationally derived and requires experimental confirmation.
When this study was published
Published in 2023, this meta-analysis incorporates data from major cardiovascular outcome trials completed in recent years. The findings align with current guidelines recommending GLP-1 RAs for cardiovascular risk reduction in type 2 diabetes.
The bigger picture
GLP-1 receptor agonists have evolved from diabetes drugs to cardiovascular protectors. This meta-analysis reinforces that weekly formulations (which improve patient adherence) provide robust cardiovascular benefits specifically in the high-risk group of diabetics with existing heart disease. The mechanistic insight about the renin-angiotensin system could guide future combination therapy strategies and help explain why GLP-1 drugs reduce strokes so effectively.
Questions still open
- Could combining GLP-1 receptor agonists with ACE inhibitors or ARBs produce synergistic cardiovascular protection through complementary renin-angiotensin system effects?
- Which of the three once-weekly GLP-1 RAs (dulaglutide, exenatide, semaglutide) provides the greatest cardiovascular benefit in head-to-head comparison?
- Does the renin-angiotensin mechanism explain why GLP-1 drugs are particularly effective at reducing stroke risk compared to other cardiovascular events?
Common questions
How do weekly GLP-1 drugs protect the heart?
Should I switch to a weekly GLP-1 drug if I have diabetes and heart disease?
Read the original research
Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
Diabetes, obesity & metabolism, 25(11), 3223-3234
Citation
Kan, Mengfan; Fu, Hui; Xu, Yunsheng; Yue, Zhaodi; Du, Bingyu; Chen, Qiang; Wang, Xueyin; Yu, Shaohong; Zhang, Zhongwen. (2023). Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.. Diabetes, obesity & metabolism, 25(11), 3223-3234. https://doi.org/10.1111/dom.15219